<p>GeneSTAR began in 1982 as the Johns Hopkins Sibling and Family Heart Study, a prospective longitudinal family-based study conducted originally in healthy adult siblings of people with documented early onset coronary disease under 60 years of age. Commencing in 2003, the siblings, their offspring, and the coparent of the offspring participated in a 2 week trial of aspirin 81 mg/day with pre and post ex vivo platelet function assessed using multiple agonists in whole blood and platelet rich plasma. Extensive additional cardiovascular testing and risk assessment was done at baseline and serially. Follow-up was carried out to determine incident cardiovascular disease, stroke, peripheral arterial disease, diabetes, cancer, and related comorbidities, from 5 to 30 years after study entry. The goal of several additional phenotyping and interventional substudies has been to discover and amplify understanding of the mechanisms of atherogenic vascular diseases and attendant comorbidities.</p>

NHLBI TOPMed: Genetic Study of Atherosclerosis Risk (GeneSTAR)

Platelet Aggregation study with SNP/CNV Genotypes (NGS), WGS data on BDC (1,787 participants)

NHLBI TOPMed: Genetic Study of Atherosclerosis Risk (GeneSTAR)

Description

Applying For Access

Summary